Situation
The U.S. biosimilars market is entering a major growth phase, with biologics representing almost half of drug spend and dozens of high-value molecules losing exclusivity over the next decade. Zydus has strong biologics manufacturing capabilities and extensive international biosimilar experience and wants to enter the U.S. to expand its global footprint.
Challenges
The U.S. market is highly competitive and structurally complex: payer/PBM contracting dominates access, buy-and-bill incentives influence provider behavior, and adoption varies significantly across therapeutic areas. The initial project prompt was broad, requiring clarity on which molecules, therapeutic areas, and capabilities would create a viable, sustainable point of entry for Zydus.
Approach
1. Conducted a full diagnostic of the U.S. biosimilars landscape across oncology, immunology, endocrinology, ophthalmology, hematology, and supportive care.
2. Built a molecule-level scoring framework evaluating market size, competitive intensity, stakeholder adoption dynamics, and Zydus feasibility.
3. Prioritized oncology and immunology as the strongest strategic fit and analyzed pathway options, regulatory expectations, and GTM considerations.
4. Developed a long-term roadmap for Zydus, including capability building, partnership models, and portfolio sequencing.
Results & Recommendation
• Oncology and immunology offer the clearest near-term entry opportunities given market attractiveness, faster adoption dynamics, and alignment with Zydus capabilities.
• Pembrolizumab (Keytruda) emerges as a top priority, with a forecasted post-LoE opportunity in the $0.6B–$1.7B range depending on competitive timing.
• Recommended that Zydus pursue a phased U.S. entry strategy anchored in
· Focused molecule selection and portfolio sequencing,
· Building U.S. regulatory + commercial capabilities,
· Early payer/PBM engagement and GTM design.
This positions Zydus for a disciplined and strategically scalable entry into the U.S. biosimilars market.